pharma · High-Grade Upper Tract Urothelial Carcinoma
Xiangya Hospital of
Xiangya Hospital of Central South University
Xiangya Hospital of is a pharma organization headquartered in CN. Primary therapeutic focus areas include High-Grade Upper Tract Urothelial Carcinoma. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 3
- Patents
- 0
Neoadjuvant Chemotherapy
Phase 2 · small molecule · High-Grade Upper Tract Urothelial Carcinoma
Neoadjuvant Chemotherapy for High-Grade Upper Tract Urothelial Carcinoma is a Phase 2 program (small_molecule) at Xiangya Hospital of Central South University with 1 ClinicalTrials.gov record(s).
Internal code XYURO001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Xiangya Hospital of Central South University
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- High-Grade Upper Tract Urothelial Carcinoma
- Status
- completed
- Trials
- 1